Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $10.8300 (0.19%) ($10.5200 - $10.8900) on Thu. Feb. 20, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.29% (three month average) | RSI | 75 | Latest Price | $10.8300(0.19%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD declines -0.6% a day on average for past five trading days. | Weekly Trend | FOLD advances 6.7% a week on average for past two weeks. | Market Behavior | Growth stock sell-off for large cap. Value stock rally for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(60%) IWO(56%) XBI(55%) IWM(53%) IWC(51%) | Factors Impacting FOLD price | FOLD will decline at least -1.645% in a week (0% probabilities). VIXM(-33%) VXX(-19%) TLT(-13%) IGOV(-2%) UNG(-1%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.645% (StdDev 3.29%) | Hourly BBV | 0 () | Intraday Trend | 0.4% | | | |
|
5 Day Moving Average | $10.88(-0.46%) | 10 Day Moving Average | $10.78(0.46%) | 20 Day Moving Average | $10.06(7.65%) | To recent high | -3% | To recent low | 22.5% | Market Cap | $2.797b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |